What is Transcode Therapeutics Inc?
, a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 20.07M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.